Biological features and outcome of biphenotypic acute leukemia: a case series
| Autor: | Mirna Sučić, Ranka Serventi-Seiwerth, Damir Nemet, Sanja Davidović-Mrsić, Mirta Mikulić, Klara Dubravčić, Dubravka Sertić, Boris Labar, Drago Batinić |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Myeloid Adolescent medicine.medical_treatment biphenotypic leukemia biological features lcsh:RC254-282 Disease-Free Survival Immunophenotyping Young Adult Biphenotypic Acute Leukemia Internal medicine White blood cell hemic and lymphatic diseases medicine Humans Young adult Aged Acute leukemia Chemotherapy business.industry lcsh:RC633-647.5 Hematology General Medicine lcsh:Diseases of the blood and blood-forming organs Middle Aged medicine.disease Prognosis lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Surgery Leukemia Biphenotypic Acute Leukemia medicine.anatomical_structure Treatment Outcome Oncology Acute Disease Female business Stem Cell Transplantation |
| Zdroj: | Hematology/Oncology and Stem Cell Therapy, Vol 1, Iss 4, Pp 225-230 (2008) |
| ISSN: | 1658-3876 |
| Popis: | BACKGROUND Biphenotypic acute leukemia (BAL) is a distinct entity that is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system and accounts for less than 5% of all acute leukemia cases. Since it is a rare and heterogeneous form of acute leukemia with an allegedly poor outcome, there is no consensus on the best treatment approach in these patients. Our objective was to analyze the biological features and outcome of patients diagnosed with BAL in our institution. PATIENTS AND METHODS Using the EGIL system, we identified 21 cases (3.9%) of BAL from 535 newly diagnosed acute leukemia patients in an 11-year period. RESULTS There were ten cases of myeloid + B-lymphoid leukemia, eight cases of myeloid + T-lymphoid, one case of B + T-lymphoid and two cases of trilineage (myeloid + B + T-lymphoid leukemia). The complete remission (CR) rate with high-dose chemotherapy was 72% and overall survival at 5 years was 21%. Patients that received acute lymphoblastic leukemia-oriented chemotherapy had a higher CR rate compared with those who received acute myeloid leukemia-oriented chemotherapy (100% vs. 60%, P = .007). The white blood cell count at diagnosis was found to have statistically significant impact on survival. CONCLUSION Despite the progress in the treatment of acute leukemia, the prognosis of BAL remains poor and treatment protocols devised explicitly for this entity should be investigated in prospective collaborative studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|